In chiip protocol why roasch is used for seminal vesicle involvement and pop RT it is for nodal risk involvement why ?
Reading File
Finding Sources
Searching the Web
CHIIP protocol prostate cancer ROACH score seminal vesicle nodal involvement RT
Searching the Web
Roach formula seminal vesicle involvement CHHiP nodal risk post prostatectomy RT RADICALS
Finding Sources
I now have enough to give a thorough answer. The CHHiP trial paper itself explains this distinction clearly. Let me synthesize.
Great question - this gets at the fundamental difference in clinical context between intact prostate RT and post-prostatectomy (post-op) RT.
Why the CHHiP Protocol Uses Two Different Roach Formulas
The Roach formulas are two separate empirical equations derived by Mack Roach et al. in the early 1990s, both using pre-treatment PSA and Gleason score - but for different anatomical risks:
Formula 1: Seminal Vesicle (SV) Involvement Risk
Used in: CHHiP (intact prostate RT)
Formula:
SV Risk (%) = PSA + 10 × (Gleason score - 6)
Cutoff used in CHHiP: < 15% = low SV risk; ≥ 15% = moderate/high SV risk
Why this formula here?
In the CHHiP protocol, the prostate is still in place. The key planning question is: how much of the seminal vesicle to include in the target volume?
- If SV risk is low (< 15%): only the prostate + base (proximal 2 cm) of SV is irradiated
- If SV risk is moderate/high (≥ 15%): the entire length of the seminal vesicles is included in the CTV
The Roach SV formula was derived from pathologic data of radical prostatectomy specimens where SV status was known. It predicts the probability of microscopic SV involvement before treatment, which directly drives contouring decisions. This formula was validated in the 1994 paper by Diaz, Roach et al. (Int J Radiat Oncol Biol Phys, PMID: 7523343) showing it predicted SV involvement better than PSA, Gleason, or stage alone.
The original CHHiP trial paper even changed its eligibility criteria mid-trial - before 2006 they used nodal risk < 30%, then updated to SV risk < 30% using this formula (reference 15 in the CHHiP paper), reflecting a shift toward this as the more relevant anatomical predictor for intact prostate treatment.
Formula 2: Nodal (Lymph Node) Involvement Risk
Used in: Post-op RT (e.g., RADICALS-RT, post-prostatectomy salvage/adjuvant RT)
Formula:
Nodal Risk (%) = 2/3 × PSA + 10 × (Gleason score - 6)
Cutoff typically used: ≥ 15% or ≥ 20% triggers inclusion of pelvic nodes in RT field
Why this formula here?
After radical prostatectomy, the seminal vesicles are already removed - so SV risk is no longer the question. The key planning question becomes: should pelvic lymph nodes be included in the salvage/adjuvant RT field?
The lymph nodes remain at risk for microscopic metastases. The nodal Roach formula (derived from the 1993-1994 Roach data using pre-prostatectomy PSA + Gleason) estimates pelvic nodal positivity risk. If this risk exceeds the protocol threshold (commonly 15%), whole-pelvis RT is added to the prostate bed RT.
Summary Table
| Parameter | CHHiP (intact prostate) | Post-op RT |
|---|---|---|
| Target organ at risk | Seminal vesicles (still present) | Pelvic lymph nodes |
| Roach formula used | SV formula: PSA + 10(GS-6) | Nodal formula: 2/3 PSA + 10(GS-6) |
| Consequence of result | How much SV to include in CTV | Whether to add pelvic nodal RT to prostate bed |
| Typical cutoff | 15% | 15-20% |
Why the SV Formula Differs from the Nodal Formula
The two formulas have different coefficients for PSA because PSA correlates differently with each risk:
- SV invasion has a more direct 1:1 relationship with PSA level, so the coefficient is 1 (no scaling)
- Nodal involvement has a weaker PSA relationship (nodes are further along in spread), so PSA is scaled by 2/3
Both formulas were derived empirically from pathologic data, not from mathematical first principles.
Clinical Bottom Line
- In CHHiP (intact prostate): the prostate is present, SV involvement is the anatomical uncertainty driving contouring, so the SV Roach formula is the right tool
- In post-op RT: the prostate and SVs are gone, nodal spread is the remaining anatomical uncertainty driving field design, so the nodal Roach formula is the right tool
It is not that one formula is "better" - they answer different clinical questions in different treatment contexts. The protocol designers correctly matched each formula to the anatomical question it was derived to answer.
I am asking about chhip vs pop RT
Searching the Web
POP-RT trial prostate pelvic nodal radiotherapy Roach formula nodal risk 20%
Searching the Web
CHHiP trial Roach seminal vesicle formula vs POP-RT nodal Roach formula difference
Now I have a clear, complete picture. Here is the precise answer:
CHHiP vs POP-RT: Why Different Roach Formulas?
Both are trials for intact prostate RT (not post-op). But they address two completely different clinical questions, which is why they use different Roach formulas.
CHHiP - Uses Roach SV (Seminal Vesicle) Formula
Formula: SV Risk (%) = PSA + 10 × (Gleason score - 6)
Cutoff: < 15% = low SV risk; ≥ 15% = moderate/high SV risk
Why? CHHiP is a hypofractionation trial (60 Gy/20f vs 74 Gy/37f). Its primary protocol question is about dose and fractionation, not nodal treatment. The SV formula is used purely for contouring decisions - how much of the seminal vesicle to include in the CTV:
- Low SV risk: include only prostate + base (proximal 2 cm) of SV
- Moderate/high SV risk: include entire SV length
CHHiP was not designed to treat pelvic nodes. It enrolled intermediate and lower-risk patients (most centers used PSA < 30 ng/mL and SV risk < 30% as eligibility). For this patient population and this trial's purpose, the relevant anatomical uncertainty is the SV, not the nodes. The SV formula tells you how far to extend the radiation field distally.
POP-RT - Uses Roach Nodal Formula
Formula: Nodal Risk (%) = 2/3 × PSA + 10 × (Gleason score - 6)
Cutoff: ≥ 20% nodal risk for eligibility (median in enrolled patients was 37.8%)
Why? POP-RT is specifically designed to answer: "Should we irradiate the pelvic lymph nodes in high-risk prostate cancer?" It randomized:
- PORT arm: Prostate + SV only (68 Gy/25f)
- WPRT arm: Prostate + SV + whole pelvis nodes (50 Gy/25f as simultaneous integrated boost to nodes)
Since the entire trial hypothesis revolves around nodal micrometastases, it logically uses the nodal Roach formula to select patients who have a meaningful risk of occult pelvic nodal disease. Using the SV formula here would be irrelevant - all these high-risk patients would already get their full SVs irradiated regardless.
POP-RT enrolled only high-risk/very high-risk patients (Gleason 8-10 with any PSA, or Gleason 7 with PSA > 15, or T3b-T4) - 80% underwent PSMA PET to exclude overt nodal disease first.
Side by Side
| Feature | CHHiP | POP-RT |
|---|---|---|
| Trial question | Optimal fractionation (hypo vs conventional) | Prostate-only vs whole-pelvis RT |
| Patient risk | Mixed intermediate/high | High and very high risk |
| Roach formula used | SV formula: PSA + 10(GS-6) | Nodal formula: 2/3 PSA + 10(GS-6) |
| Purpose of Roach | Contouring - how much SV to include | Eligibility - does this patient have occult nodal risk? |
| Nodes treated? | No | Yes (WPRT arm) |
| Cutoff | 15% SV risk | 20% nodal risk |
The Core Logic
The formula chosen in each trial matches the anatomical question being asked:
- If your question is "are the seminal vesicles at risk?" → use the SV Roach formula (CHHiP)
- If your question is "are the pelvic lymph nodes at risk?" → use the nodal Roach formula (POP-RT)
The two formulas have different PSA coefficients (1 vs 2/3) because PSA correlates more strongly with SV invasion (direct local extension) than with nodal spread (which requires more advanced disease biology). So the same PSA value implies a higher SV risk than nodal risk, which is why the nodal formula scales PSA down by 2/3.
How for we decide if nodal irradiation in post op N0 disease
Searching the Web
pelvic nodal irradiation post prostatectomy pN0 salvage adjuvant RT decision criteria RADICALS GETUG
Searching the Web
post radical prostatectomy pN0 whole pelvis RT vs prostate bed only Roach formula criteria 2023 2024
Searching the Web
SPPORT trial post prostatectomy whole pelvis salvage RT pN0 criteria results
Now I have enough to give a thorough, structured answer.
Deciding Nodal Irradiation in Post-Op pN0 Disease
This is one of the more nuanced decisions in prostate radiation oncology. Here is how it is approached:
The Core Problem
The patient is pathologically node-negative (pN0) - meaning lymph nodes were removed and found clear at surgery. But pN0 is not the same as "truly node-free" because:
- Limited PLND - most centres only do a standard obturator/external iliac dissection, missing common iliac and presacral nodes
- Sampling error - microscopic deposits < 2 mm are frequently missed on pathology
- Occult nodal disease still exists in a subset of pN0 patients, proportional to the original disease biology
So the question is: does the original pre-operative biology justify adding pelvic nodal RT to the prostate bed RT?
How to Estimate Nodal Risk in the Post-Op Setting
Since the prostate is gone, you use pre-operative clinicopathological variables to estimate the residual occult nodal risk:
Roach Nodal Formula (based on pre-op PSA and Gleason):
Nodal Risk (%) = 2/3 × PSA + 10 × (Gleason score - 6)
- ≥ 15% is the commonly used threshold (as per RTOG 0924)
- Some protocols use ≥ 20% (as in POP-RT, though that was for intact prostate)
Pathological features at RP that additionally push toward nodal RT:
| Feature | Significance |
|---|---|
| pT3b (SVI) | Very high risk of nodal spread |
| Gleason 8-10 (Grade Group 4-5) | Aggressive biology |
| Pre-op PSA > 20 ng/mL | High burden |
| Positive surgical margins + extraprostatic extension | Residual/systemic risk |
| Inadequate PLND (< 10 nodes sampled) | Less confidence in pN0 |
Key Trial Evidence: SPPORT (NRG/RTOG 0534)
This is the most important RCT specifically in the post-prostatectomy salvage RT setting with pN0 patients. It had 3 arms:
- Arm 1: Prostate bed RT alone (64.8-70.2 Gy)
- Arm 2: Prostate bed RT + short-term ADT (4-6 months)
- Arm 3: Prostate bed RT + short-term ADT + pelvic nodal RT (45 Gy)
Results at 5 years:
| Arm | 5-yr Freedom from Progression |
|---|---|
| Bed only | 71.7% |
| Bed + ADT | 82.7% |
| Bed + ADT + pelvic nodes | 89.1% |
Adding pelvic nodal RT gave a 6.1% absolute improvement in freedom from progression over bed + ADT alone (p = 0.0027), and reduced distant metastasis risk (HR 0.52, p < 0.001) and prostate cancer death (HR 0.51, p = 0.007).
Eligibility in SPPORT: PSA 0.1-2.0 ng/mL at salvage, any pN0 with adverse features (pT3, Gleason 7-10, positive margins, SVI).
Current Clinical Decision Framework (Post-Op pN0)
Step 1 - Is nodal RT even being considered?
- Patient must have adverse pathology: pT3a/b, Gleason ≥ 7, SVI, positive margins
- pN0 but with inadequate PLND (< 10 nodes) = treat as if nodal status unknown
Step 2 - Estimate residual nodal risk
- Apply Roach nodal formula to pre-op PSA + Gleason
- ≥ 15-20% nodal risk → consider adding pelvic nodal RT
Step 3 - Additional factors favouring pelvic nodal RT:
- pT3b (seminal vesicle invasion) - strongest single predictor
- Gleason 8-10
- Pre-op PSA > 20 ng/mL
- Multiple adverse features combined
- PSA persistence post-RP (never became undetectable)
Step 4 - Is ADT being given?
- SPPORT showed benefit of nodal RT only in conjunction with ADT - pelvic nodal RT alone (without ADT) in post-op setting has weaker evidence
- AUA/ASTRO/SUO Guideline 2023: "In patients with BCR following RP undergoing salvage RT with ADT, clinicians may use expanded fields including regional lymph nodes" (Conditional recommendation, Grade B)
Decipher Genomic Classifier (Emerging)
A subgroup analysis of SPPORT showed that Decipher score independently predicts:
- Which pN0 patients have occult nodal disease
- Which patients benefit most from pelvic nodal RT intensification
Patients with high Decipher score (≥ 0.6) derived the greatest benefit from adding nodal RT. This is increasingly being used in practice at high-volume centres to refine the decision beyond just Roach formula alone.
Practical Summary
| Clinical Scenario | Decision |
|---|---|
| Low-risk path (pT2, GS ≤ 6, PSA < 10), pN0 | Prostate bed only |
| Adverse features (pT3, GS ≥ 7) but Roach nodal risk < 15% | Prostate bed ± ADT; nodes optional |
| pT3b (SVI), Gleason 8-10, or Roach nodal ≥ 15-20% | Prostate bed + ADT + pelvic nodes (SPPORT-based) |
| Limited PLND or no PLND done at surgery | Treat more liberally with nodal RT |
| PSA persistence (never undetectable post-RP) | High-risk biology → favour nodal RT |
The key principle: pN0 is not equivalent to N0 biologically. When original disease biology (high Gleason, high PSA, SVI, inadequate PLND) creates meaningful doubt about true nodal status, adding pelvic nodal RT to salvage/adjuvant RT with ADT is supported by Level 1 evidence from SPPORT.
This is a shared conversation. Sign in to Orris to start your own chat.